Isolation of azatyrosine-induced revertants from ras-transformed human mammary epithelial cells
Related Experiment Video
Updated: Aug 11, 2026

De Novo Generation of Somatic Stem Cells by YAP/TAZ
Published on: May 7, 2018
N Kyprianou1, J Taylor-Papadimitriou
1Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK.
Abstract:
Non-transformed revertant clones were isolated from the ras-transformed MTSV1-7 (ras) cell line, after treatment with the antibiotic azatyrosine. Azatyrosine significantly inhibited the growth of the ras-transformed cells but not of the normal MTSV1-7. After 7 days of azatyrosine treatment, approximately 30% of MTSV1-7 (ras) cells survived, and revertant cell lines were selected by random cloning. The azatyrosine-induced revertants (six clones) were considered non-transformed on the basis of (a) their substantially reduced ability to form colonies in soft agar, and (b) their inability to produce tumours in nude mice. Molecular analysis of the revertants revealed that each contains multiple copies of the v-H-ras gene and expresses high levels of v-H-ras mRNA, and all revertants sustain elevated levels of p21ras protein. Thus, the revertant phenotype induced by azatyrosine does not result from inactivation of v-H-ras oncogene or inhibition of its expression. In vivo guanine nucleotide binding to p21ras in the revertant cell lines demonstrated binding of both GTP and GDP, indicating that reversion to the non-transformed phenotype was not due to inability of p21ras to bind GTP. The expression of the human K-rev-1 gene, a known tumour-suppressor gene in ras-transformed NIH3T3 cells, was studied in the isolated azatyrosine revertants. All six revertants showed a significant increase in the K-rev-1 transcript levels compared with the ras-transformed MTSV1-7 cells. These results suggest that tumorigenic transformation of human mammary epithelial cells by v-H-ras may be influenced by the level of expression of the tumour-suppressor gene, K-rev-1.
Insights
Azatyrosine treatment induced non-transformed revertants from ras-transformed cells. Reversion was linked to increased expression of the K-rev-1 tumor-suppressor gene, not v-H-ras oncogene inactivation.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Ras-transformed cells exhibit uncontrolled growth and tumor formation.
- Azatyrosine is an antibiotic with potential anti-cancer properties.
- Understanding mechanisms of tumor suppression is crucial for cancer therapy.
Purpose of the Study:
- To investigate the mechanism by which azatyrosine induces reversion of ras-transformed cells.
- To identify molecular changes associated with the non-transformed phenotype.
- To explore the role of the K-rev-1 tumor-suppressor gene in ras-mediated transformation.
Main Methods:
- Isolation and characterization of azatyrosine-induced revertant cell lines.
- Soft agar colony formation assays and nude mouse tumorigenicity studies.
- Molecular analysis including gene expression (mRNA) and protein levels (p21ras).
- Guanine nucleotide binding assays for p21ras.
- Quantitative analysis of K-rev-1 gene expression.
Main Results:
- Azatyrosine treatment yielded non-transformed revertant clones from ras-transformed cells.
- Revertants showed reduced anchorage-independent growth and tumorigenicity.
- Revertant cells maintained high levels of v-H-ras oncogene, mRNA, and p21ras protein.
- p21ras in revertants retained the ability to bind GTP.
- All revertants exhibited significantly increased K-rev-1 tumor-suppressor gene transcript levels.
Conclusions:
- Azatyrosine-induced reversion is not due to v-H-ras oncogene inactivation or impaired GTP binding.
- Increased expression of the K-rev-1 tumor-suppressor gene is associated with the non-transformed phenotype in these revertants.
- Tumorigenic transformation by v-H-ras may be modulated by K-rev-1 expression levels.

